Skin Health and Aesthetics Powered by Nobel Prize-Winning Regenerative Medicine Technology

First to Commercialize 2+ Decades of Cellular Reprogramming R&D. Others have raised billions from Bezos, Altman, Armstrong, Schmidt, Thiel to pursue this science—still in the lab. We've commercialized it. 100% efficacy and poised to go to market.

Clinical validation completed at FDA-registered facility: 100% efficacy rate with 28% wrinkle reduction and 24% elasticity improvement. Both safety and efficacy trials done—rare at JPM.

We follow the Tesla model—premium early adopters first, then mass markets through bio-manufacturing economies. Operating AI-native with <10 people, we compress R&D from 12 months to 3.

Market opportunity: GLP-1 medications have created "Ozempic face," expanding the $270B convergence market across topicals, injectables, and procedures.

Team has multiple exits (including to KKR), scaled consumer health to $4M MRR, and holds 20+ patents.